• Cue Biopharma to Host Business Update Call and Webcast

    来源: Nasdaq GlobeNewswire / 10 8月 2021 08:00:01   America/New_York

    CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Tuesday, August 17, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website.

    Members of the Cue Biopharma executive management team will provide a clinical update from the Company’s clinical trials with CUE-101, its lead and representative IL-2 based drug product candidate from the CUE-100 series. CUE-101 is currently in a Phase 1b clinical trial for the treatment of HPV+ recurrent/metastatic head and neck squamous cell carcinoma. The discussion will focus on data updates from the Phase 1a/b monotherapy dose escalation and expansion trials, the combination trial evaluating CUE-101 front line with Merck’s pembrolizumab (KEYTRUDA®) and the upcoming neoadjuvant trial. Management will also provide an update on the Company’s technology platform developments and pipeline development progress from the IL-2 based CUE-100 series including CUE-102, as well as updates on its strategic objectives and anticipated milestones.

    Webcast Details 
      
    Tuesday, August 17, 2021 at 4:30 p.m. EDT  
    Investors:877-407-9208
    International: 201-493-6784
    Conference ID: 13721829
    Webcast:  http://public.viavid.com/index.php?id=145891

    About Cue Biopharma
    Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body to transform the treatment of cancer, infectious disease and autoimmune disease. The company’s proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.

    Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

    For more information, visit www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.

    Investor Contact
    George B. Zavoico, Ph.D.
    VP, Investor Relations & Corporate Development
    Cue Biopharma, Inc.
    gzavoico@cuebio.com

    Media Contact
    Darren Opland, Ph.D.
    LifeSci Communications
    darren@lifescicomms.com

     


    Primary Logo

分享